Anthrax drug under the microscope: will it save lives?

NCT ID NCT03569514

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up to 10 people with severe anthrax who receive a treatment called AIGIV. Researchers will track how many patients survive and whether the drug causes serious side effects. The goal is to learn more about how well AIGIV works and how it behaves in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTHRAX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anthrax infection bacterial infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••